Holen Sie sich die Stockscreener-App
4.979
3.56%
-0.071
Schlusskurs vom Vortag:
$5.05
Offen:
$4.95
24-Stunden-Volumen:
4,279
Relative Volume:
0.50
Marktkapitalisierung:
$69.45M
Einnahmen:
$57.94M
Nettoeinkommen (Verlust:
$-2.34M
KGV:
-29.89
EPS:
-0.1666
Netto-Cashflow:
$3.82M
1W Leistung:
-5.44%
1M Leistung:
-6.17%
6M Leistung:
-18.43%
1J Leistung:
-26.32%
1-Tages-Spanne:
$4.85
$5.08
1-Wochen-Bereich:
$4.85
$5.51
52-Wochen-Spanne:
$4.83
$8.74
Champions Oncology Inc Stock (CSBR) Company Profile
Firmenname
Champions Oncology Inc
Sektor
Branche
Telefon
410-369-0365
Adresse
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
4.99 | 70.29M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-12 | Hochstufung | Craig Hallum | Hold → Buy |
| 2019-11-18 | Eingeleitet | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Aktie (CSBR) Neueste Nachrichten
CSBR Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026 - ACCESS Newswire
A cancer research company will report results Sept. 10 - Stock Titan
CSBR - Finviz
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging - New Castle News
New imaging follows cancer treatments inside tumors—and links uptake to response - Stock Titan
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Champions (CSBR) Range: Finishes 4.86% Up at $5.18 in the Latest Session; Price Setup: the Near-Term Reference Band Stretches From $4.92 to $5.44 in the Available RecordHidden Order - vinanet.vn
North-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Japan Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Rest-Of-Asia-Pacific Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Latin-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Comedian Michael Kosta Headlines Karmanos Comedy Champions on New October Date, Hosted by 101 WRIF's Jade Springart - PR Newswire
Precision Trading with Champions Oncology Inc. (CSBR) Risk Zones - Stock Traders Daily
OSTX Stock Price and Chart — AMEX:OSTX - TradingView
Manulife China Bank Life Champions Early Health Action and Financial Planning at The Art of Longevity - Mindanao Times
Residential Social Vulnerability Associated With Worse Survival Among Black Women With Epithelial Ovarian Cancer - The ASCO Post
China Patient Derived Xenografts/PDX Models Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
NMAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oil Prices Rise as Iran Draft Plan Proposes Barring U.S. and Israel From Strait of HormuzAnnual Report - Vinanet
Technical Reactions to CSBR Trends in Macro Strategies - Stock Traders Daily
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Champions Oncology (CSBR) Pulls Back 2.7% as Shares Test Support Near $5.33Double EMA - dars.gov.et
Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR - TradingView
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - theglobeandmail.com
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... By GuruFocus - Investing.com Canada
AgomAb Therapeutics (AGMB) Holds Steady Near Resistance as Biotech Sector Shows Mixed SentimentHead and Shoulders - vinanet.vn
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue By Investing.com - Investing.com Nigeria
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue - Investing.com
CSBR: Record revenue and positive Adjusted EBITDA achieved, with strong core services growth and margin gains - TradingView
CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary - TradingView
CSBR: Revenue up 4.4% to $59.4M, but net loss of $1.2M driven by higher R&D and operating costs - TradingView
Rising costs push Champions Oncology (NASDAQ: CSBR) into 2026 loss - Stock Titan
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 - marketscreener.com
Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026 - TradingView
CSBR: Record revenue and positive adjusted EBITDA achieved, driven by core research services growth - TradingView
CHAMPIONS ONCOLOGY ($CSBR) Releases Q4 2026 Earnings - Quiver Quantitative
Champions Oncology Q4 revenue rises; margin improves driven by cost discipline - TradingView
Champions Oncology Reports Record Annual Revenue of $59 Million - ACCESS Newswire
BRIEF-Champions Oncology Q4 Adjusted EPS USD 0.01 - TradingView
At fiscal year-end, Champions Oncology had $4.9M cash, no debt - Stock Titan
Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CSBR|Champions Oncology Inc|Price:6.160|Chg%:+0.030 - TradingKey
Finanzdaten der Champions Oncology Inc-Aktie (CSBR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):